CLL Topics Banner: Therapies, Research and Patient Education for Chronic Lymphocytic Leukemia
CLL Topics Home Navigation Topics Alert Learning Tools About Us Feedback Feedback
Full Menu


  • el
  • pt
  • French Impressionist

    Index of Articles

    Updated: August 9, 2024

    Follicular Lymphoma

    Phase III Clinical Trial of Single-Agent HuMax-CD20

    Seeking Approval on Different Fronts

    electric cascade In mid-2006 Genmab announced the launch of a second pivotal phase III clinical trial of HuMax-CD20 as a single agent: this time for treating follicular lymphoma patients who have failed chemoimmunotherapy combinations incorporating Rituxan or Rituxan given as maintenance therapy. While the trial is interesting in itself as expanding the options for follicular lymphoma patients, it also serves as another clinical platform to demonstrate the theoretically superior efficacy of HuMax-CD20 when compared to Rituxan. The results of this clinical trial should be of interest to CLL patients since approval for the treatment of follicular lymphoma would put HuMax-CD20 in an FDA approval status similar to that of Rituxan. Read the details in HuMax-CD20 Monotherapy in Refractory Follicular Lymphoma.



    HuMax-CD20 plus Fludarabine plus Cyclophosphamide

    Genmab's New Phase II H+FC Clinical Trial

    electric cascade Genmab has recently launched a chemoimmunotherapy combination clinical trial involving its anti-CD20 monoclonal antibody, HuMax-CD20 (generic name ofatumumab). This is a phase II dose comparison trial. The Genmab protocol combines HuMax-CD20 with fludarabine and cyclophosphamide over a 6 month treatment cycle. The trial is currently being offered at four recruitment centers in the United States. There is reason to hope that HuMax-CD20 will be more effective than Rituxan both as a single agent as well as in chemoimmunotherapy combinations such as this. You can find our discussion of this announcement at: HuMax+FC Announcement.


    HuMax-CD20: Risks and Rewards

    Belt, Suspenders and Cummerbund

    Get to Know Ofatumumab

    electric cascade HuMax-CD20 derives part of its improved efficacy from its capacity to work with a patient's complement system to destroy B-cells. In HuMax-CD20 Risks and Rewards, we examine the potential risks of complement depletion that may accompany intensive treatment with this monoclonal antibody — and suggest a possible precautionary measure for those who are taking part in the Phase III trial of this agent for fludarabine- and Campath-refractory patients.



    A Smarter Monoclonal on Trial

    What Makes HuMax-CD20 Different from Rituxan?

    Apples2Apples In this article we take a closer look at the new agent starring in Genmab's recently announced Phase III clinical trial for fludarabine and Campath refractory CLL patients. This well-designed trial keys in on HuMax-CD20's strengths which we hope will provide significantly better results than singe-agent Rituxan, especially in this difficult patient cohort. To learn more about this pivotal trial and to understand how this important new monoclonal antibody works, read A Smarter Monoclonal on Trial.


    Genmab in the News

    HuMax-CD20 in Action

    Harvey is Back!

    companions We have an opportunity to see HuMax-CD20 in action when Harvey and Serena pack their bags and travel to England in pursuit of therapy with this new agent. To learn more, read: Genmab in the News.


    HuMax Clinical Trial

    Early Results from GenMab's Anti-CD20 Monoclonal Antibody

    The Half-Full Glass

    half-full glass We have high hopes for the new generation of monoclonal antibodies that are under development and have discussed new trials under way to test these agents in the clinic. Early results form one such trial, involving GenMab's HuMax, were highlighted at the 2005 ASH conference in Atlanta. We offer our analysis of the published results in Results from GenMab's HuMax Clinical Trial.


    Monoclonal Antibodies

    Sons of Rituxan and Campath

    A New Generation of More Effective Antibodies Makes It into the Clinic

    lobster The monoclonal antibodies Rituxan and Campath have changed the landscape for CLL and a whole range of hematological conditions. New improved versions of these monoclonal antibodies are now coming out of the lab and into the clinic. In our article Sons of Rituxan and Campath, we examine the mechanisms by which these agents achieve their effects - and the methods for increasing their efficacy. Read about a new CD20 monoclonal antibody, HuMax from GenMab, now in clinical trials in Europe and in the US and, incidentally, satisfy your curiosity about why we have a picture of a lobster gracing this paragraph.




    Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.

    Copyright Notice:

    Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.

    All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

    However, you may download and print material from exclusively for your personal, noncommercial use.


    Tivoli Gardens, Copenhagen


    Topic: HuMax-CD20

    up arrow